Chris Leamon

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

Hamilton, Canada and Boston, USA.   2 November 2021.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer.  Dr Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals. “Chris’ expertise …

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer Read More »